The research included 4,401 sufferers, aged 30 and older, with sort 2 diabetes and continual kidney illness. These sufferers have been randomly assigned at 690 websites in 34 international locations to take both canagliflozin or a placebo, from March 2014 by Could 2017.
They have been adopted up with at 3, 13 and 26 weeks, throughout which the consequences of the drug have been monitored.
The researchers discovered that within the canagliflozin group the relative threat of loss of life from renal causes was 34% decrease, and the relative threat of end-stage kidney illness was 32% decrease. The group additionally had a decrease threat of cardiovascular loss of life, coronary heart assault, stroke and hospitalization for coronary heart failure.
Based mostly on knowledge within the research, the researchers estimated that canagliflozin therapy would stop 22 hospitalizations for coronary heart failure and 25 composite occasions of cardiovascular loss of life, coronary heart assault or stroke amongst 1,000 sufferers.
The research had some limitations, together with that it didn’t embrace sufferers who had very superior kidney illness. Nor did it embrace sufferers whose kidney illnesses have been believed to be because of circumstances apart from sort 2 diabetes. Extra analysis is required to find out whether or not the research’s findings might be generalized to different sorts of kidney illness.
“With this entire class of medication, we actually do want to consider how we’re utilizing it, due to the guts advantages and the kidney advantages,” Molitch stated about SGLT2 inhibitors.
“This class of medication actually has its main motion on the kidney, from a diabetes perspective. So usually we’ve got plenty of glucose — the principle sugar that is circulating within the blood — after which the kidney filters that glucose. And so more often than not there is no glucose within the urine as a result of the kidney reabsorbs all of the glucose that is filtered out of the blood,” he stated. “What these medication do is that they block that reabsorption of glucose again into the blood from the urine. And so then you definately excrete plenty of the glucose out into the urine.”
“We’re nonetheless not precisely certain what the mechanisms are that trigger these coronary heart and kidney advantages, however they’re clearly not solely because of reducing the blood sugar degree,” he stated.
“The center and kidney advantages happen in sufferers with extra superior kidney illness, in whom the blood glucose reducing results of canagliflozin can be minimal,” he stated. “So, on the idea of this research, we’d use canagliflozin only for kidney advantages and presumably coronary heart advantages whereas utilizing different medication to regulate glucose ranges in sufferers with diabetes and kidney illness.”
“This trial was designed to incorporate people who had diabetic renal illness, and as such, is the primary instance of a reducing of threat for kidney failures [as] nicely as improved cardiovascular outcomes,” stated Leroith, who was not concerned within the research. “I consider the paper is extraordinarily important and may have a broadly learn viewers with main implications.”